52results about How to "Lower drug concentration" patented technology

The present invention relates to conjugates of water-soluble polymers and o-(chloracetyl-carbamoyl) fumagillol (TNP-470) and use of those conjugates as specific intracellular carriers of the TNP-470 into tumor vessels. The present invention further relates to use of those conjugates to lower the neurotoxicity of TNP-470. Preferably, the polymer has a molecular weight in the range of 100 Da to 800 kDa. More preferably, the polymer has a molecular weight no greater than 60 kDa. Most preferably, the polymer has a molecular weight in the range of 15 kDa to 40 kDa.

The present invention relates to conjugates of water-soluble polymers and o(chloracetyl-carbamoyl) fumagillol (TNP-470) and use of those conjugates as specific intracellular carriers of the TNP-470 into tumor vessels. The present invention further relates to use of those conjugates to lower the neurotoxicity of TNP-470. Preferably, the polymer has a molecular weight in the range of 100 Da to 800 kDa. More preferably, the polymer has a molecular weight no greater than 60 kDa. Most preferably, the polymer has a molecular weight in the range of 15 kDa to 40 kDa.

Disclosed are: a composition which enables the more effective development of the efficacy of a water-soluble medicinal agent in a solution containing the medicinal agent; and a dispersion in which a hydrophobic medicinal agent can be dispersed stably without requiring the use of any surfactant. Specifically disclosed are: a composition comprising ultra-fine air bubbles having a most frequent particle diameter of 500 nm or less, a medicinal agent and water; and a process for producing a composition comprising ultra-fine air bubbles having a most frequent particle diameter of 500 nm or less, a medicinal agent and water, which utilizes an ultra-fine air bubble generation apparatus.

The invention provides a preparation method of a slow-release pain-easing antibacterial absorbable dressing. The preparation method includes the following steps that a, a spinning solution A is prepared; b, a spinning solution B is prepared; c, electrostatic spinning is conducted, wherein the spinning solution A in the step a and the spinning solution B in the second b are added into an electrostatic spinning device comprising two single-channel injection pumps and subjected to electrostatic spinning, so that electrostatic spinning fiber membranes are obtained, wherein the included angle formed by single-axis spray nozzles (2) of the two single-channel injection pumps (1) is 60-180 degrees; d, the electrostatic spinning fiber membranes are crosslinked fixedly. Through the preparation method of the slow-release pain-easing antibacterial absorbable dressing, the speed of diffusing medicine in a carrier is decreased, release time is prolonged, the medicine is released gradually on the wounded part, and the effective medicine concentration of the wounded part can be kept for a long term. The invention further provides the slow-release pain-easing antibacterial absorbable dressing.

This invention is in the field of chemical restructuring of pharmaceutical agents known to cause tissue toxicity as a side effect, by producing their orotate derivatives. More particularly, it concerns orotate derivatives of the anthracyclines, doxorubicin and daunorubicin, that are found to reduce levels of the pharmaceutical agent in noncancerous tissues. There orotate derivatives are equally efficacious in inhibiting the SCCAKI-1 kidney tumor in animals and the reduction in the heart tissue of doxorubicin compared with doxorubicin HCl suggests a reduction in toxicity induced by free radical generation by the anthrracyclines.

The invention belongs to the field of medicine preparation, and particularly relates to application of robenidine hydrochloride in preparation of medicine for treating fungal infection. Experiments prove that the minimum bacteriostatic concentration of the robenidine hydrochloride is 4 mu M, and is lower than that of fluconazole which is a common antifungal drug, the bacteriostatic effect of the robenidine hydrochloride is more obvious at the same concentration dose, the robenidine hydrochloride still has a good killing effect on drug-resistant fungal strains and super fungi, the toxicity is low, and the robenidine hydrochloride is safe and reliable. The invention also finds that the cell wall and the transcription factor RLM1 are drug targets of robenidine hydrochloride for treating fungal infection, and provides broad prospects for drug treatment of fungal infection.

The invention relates to a PLGA / FK506 drug-loading nano microsphere and a preparation method and an application thereof. The preparation method for the drug-loading nano microsphere comprises the following steps: firstly adding a nonionic surfactant to deionized water and forming a water phase, enabling PLGA and FK506 to be successively dissolved in an organic solvent and forming an oil phase, after that, dropwise slowly adding the oil phase to a vortex center of the water phase, after high-speed stirring and ultrasonic treatment, acquiring O / W-type emulsion; and stirring the acquired O / W-typeemulsion in a room temperature condition under a low speed so that the organic solvent is completely volatilized, acquiring nano microsphere turbid liquid, finally centrifuging, washing, and drying to obtain a target product, wherein a particle size of the product is 100-200 nm preferably. Drug-loading capacity of the prepared PLGA / FK506 drug-loading nano microsphere reaches 17.64%, and encapsulation efficiency reaches 77.08%. Active targeting performance of the drug-loading microsphere is advantageously improved, and drug slow release and stronger effect of inhibiting growth of scar cells are realized.

The invention provides a new detection index for drug sensitivity under the state of an inflammatory bowel disease and application of the new detection index in the design of a drug therapy scheme, relates to multiple fields of pharmaceutical pharmacokinetics, pharmacology, cytobiology and molecular biology, creatively reveals natural drug-resistant phenomena of the inflammatory bowel disease and expounds related mechanisms. According to the new detection index, the phosphorylation of STAT3 is promoted by virtue of cell factors TNF-a, IL17 and LPS, which are excessively secreted in mice with the inflammatory bowel disease, in a way of STAT3 / Nf-kb, then the phosphorylation and the nuclear translocation of P65 are induced, the expression of peripheral blood monouclear cells P-gp is promoted, and the drug concentration of an immune inhibitor in the cells is reduced, the treatment effect of the immune inhibitor is inhibited, and the natural drug resistance is generated; by administering a P-gp specific inhibitor, the drug resistance phenomenon can be reverted. The new detection index prompts that P-gp expression quantity of peripheral blood lymphocyte can serve as an evaluation index of the natural drug resistance of patients with IBD (inflammatory bowel disease), and by virtue of the combination of the P-gp inhibitor, the decrease of the pharmaceutical effect caused by the natural drug resistance can be reverted, so that a new thought is provided for the treatment scheme of IBD.

The invention discloses an application of nitazoxanide and tizoxanide in the preparation of a drug for resisting porcine reproductive and respiratory syndrome viruses, and an application of a pharmaceutical preparation in the preparation of a drug for resisting porcine reproductive and respiratory syndrome virus infection. It is found in the invention that nitazoxanide and / or tizoxanide and pharmaceutically acceptable salts thereof can effectively protect animal cells at a low drug concentration, and the drug concentration can reach a micromole concentration level. It is also found in the invention that nitazoxanide and / or tizoxanide and pharmaceutically acceptable salts thereof can protect cells from virus infection and reduce the amount of nucleic acid of viruses in cells.

The invention relates to a drug inclusion compound of tilmicosin and its preparation and application. In the preparation method, the insoluble tilmicosin drug is first loaded onto nano-silica, and by adjusting the amount of tilmicosin and nano-silica sol in the preparation process of the inner core particles, a compound accounting for 80% of the total weight of the drug 90% of the inner core particles loaded with tilmicosin; and then coated with a coating solution made of resin, talcum powder, alcohol, surfactant, etc., to obtain the tilmicosin drug inclusion compound. After the drug inclusion compound is loaded with nano-silica, the drug concentration in saliva is reduced. At the same time, the drug-loaded particles are coated by inclusion technology, which not only achieves double taste-masking effects, but also plays a role in sustained release. role. In addition, the process of preparing the coating liquid in the present invention is simple, and after the coating is completed, the alcohol evaporates after being dried, so that the ingredients contained in the coating can be reduced without changing the coating effect.

The invention relates to a triptolide compound composition as well as a preparation method and application thereof, and belongs to the technical field of medicines. The triptolide compound compositionhas an obvious effect-enhancing and toxicity-reducing effect. The triptolide compound composition is prepared from triptolide, an ammonium glycyrrhizinate phospholipid compound, an emulsifier, oil, awater-soluble stabilizer, a fat-soluble stabilizer, glycerol, a co-emulsifier and water according to the following ratio, by weight percentage, 0.01%-0.02% of triptolide, 0.1%-0.9% of the ammonium glycyrrhizinate phospholipid complex, 5%-15% of oil, 0.9%-2.7% of the emulsifier, 0.3%-0.9% of the fat-soluble stabilizer, 2.5% of glycerol, 0.05%-0.1% of the co-emulsifier, 0%-0.2% of the water-solublestabilizer and the balance of water. The triptolide and the ammonium glycyrrhizinate are matched for use, the ammonium glycyrrhizinate is used for protecting cells such as livers and kidneys of organisms from being damaged by the triptolide, and the phospholipid complex prepared from the special structure of the ammonium glycyrrhizinate is high in lipophilicity, high in bioavailability and high in preparation stability, so that the treatment effect is improved.

The invention discloses medicinal preparations for treating inner ear diseases by transtympanic administration, which comprise interferon or interferon derivatives thereof serving as a main composition. The medicinal preparations are various transtympanica administration preparations consisting of the interferon and medicinal auxiliary materials, such as a liquid agent, spraying agent, a gelata, an ointment, a fine granule or microparticles and compound preparations combined by other formulations. The medicinal preparations are quick and efficient for treating the inner ear diseases, can improve the concentration of the medicament in the inner ear, have high local biological utilization, and avoid frequent, large-quantity and long-term administration.